Selank Eliminated Anxiety and Pain Sensitivity During Alcohol Withdrawal in Rats

A single intraperitoneal injection of selank at 0.3 mg/kg eliminated anxiety caused by alcohol withdrawal in rats, as measured by the elevated plus maze and social interaction tests. Selank also prevented the development of mechanical allodynia (pain hypersensitivity) — a common withdrawal symptom. Notably, selank reduced withdrawal symptoms without affecting the rats' ethanol consumption, meaning it treated the withdrawal without changing drinking behavior.

Outbred rats were given 10% ethanol as their only fluid source for 24 weeks to establish stable alcohol dependence. Alcohol-preferring animals (consuming >5.0 g/kg/day) were selected. After 48 hours of acute withdrawal, rats received a single intraperitoneal injection of selank (0.3 mg/kg). Anxiety was measured using the elevated plus maze and social interaction tests. Pain sensitivity (mechanical allodynia) was also assessed. A free-choice ethanol/water test measured whether selank affected drinking behavior.

Alcohol withdrawal is a dangerous medical condition that can include severe anxiety, pain sensitization, seizures, and even death. Current treatments (primarily benzodiazepines) carry their own addiction risk. Selank — a synthetic peptide anxiolytic derived from the natural immunopeptide tuftsin — showed the ability to address both the anxiety and pain components of withdrawal without sedation or affecting alcohol intake, suggesting it could be a safer alternative.

Selank is a Russian-developed heptapeptide that has been approved in Russia as an anxiolytic. It's derived from tuftsin, a naturally occurring immunomodulatory peptide. This study adds to a body of Russian-language research suggesting selank has legitimate anti-anxiety properties without the sedation, tolerance, or addiction risk associated with benzodiazepines. The dual action against both anxiety and pain during withdrawal is particularly interesting, as these symptoms often drive relapse. However, selank remains largely outside Western regulatory frameworks.

This is a rat study with a single dose and single time point — it doesn't address whether selank works with repeated dosing or during prolonged withdrawal. Intraperitoneal injection doesn't reflect typical human administration routes. The study used outbred rats selected for alcohol preference, which may not model all human alcohol dependence patterns. Sample sizes are not specified in the abstract.